CVS Group plc, a leading provider of integrated veterinary services in the UK, has released a notification regarding its existing block listing arrangements. The company has outlined the details of its block listing interim review, in accordance with the AIM Rules for Companies. The block listing arrangements pertain to several share schemes, including the 2017-2020 Sharesave Scheme, the 2018-2021 SAYE Sharesave Scheme, the CVS Group SAYE Plan, and the CVS Long Term Incentive Plan 2017.
The report covers the period from 12 July 2023 to 12 January 2024, detailing the balance of unallotted securities under the schemes, any increases in the block scheme, and the number of securities issued or allotted during the period. It also provides the balance under the schemes not yet issued or allotted at the end of the period. The notification includes the number and class of securities originally listed and the date of admission for each.
The company has confirmed that all outstanding share awards under the 2017 Sharesave Scheme have now vested or lapsed, and all outstanding options under the 2018 SAYE Sharesave Scheme have been exercised or have lapsed. Consequently, the block listings associated with these share plans have been cancelled, and the provided details represent their final block listing return.
CVS Group plc has ordinary shares of 0.2 pence each block listed under the 2017-2020 Sharesave Scheme and the 2018-2021 SAYE Sharesave Scheme. The announcement also includes contact information for CVS Group plc and its advisors, including Peel Hunt LLP and Berenberg, for further inquiries.
This notification provides transparency regarding CVS Group plc's block listing arrangements and the status of its share schemes, offering insight into the company's equity-related activities and compliance with regulatory requirements.